{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:50:14Z","timestamp":1792525814894,"version":"4.5.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002261","name":"Russian Foundation for Basic Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002261","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.intimp.2025.115519","type":"journal-article","created":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T12:02:12Z","timestamp":1757592132000},"page":"115519","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["The role of 5-HT2B-serotonin receptor in the modulatory effect of fluoxetine on interaction of macrophages with CD4+ T-cells in multiple sclerosis."],"prefix":"10.1016","volume":"165","author":[{"given":"Anna","family":"Lopatina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Murugina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Murugin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail","family":"Pashenkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail","family":"Melnikov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.intimp.2025.115519_bb0005","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrneurol.2016.187","article-title":"Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis","volume":"13","author":"Olsson","year":"2017","journal-title":"Nat. Rev. Neurol."},{"issue":"11","key":"10.1016\/j.intimp.2025.115519_bb0010","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s11910-013-0398-4","article-title":"Stress in multiple sclerosis: review of new developments and future directions","volume":"13","author":"Lovera","year":"2013","journal-title":"Curr. Neurol. Neurosci. Rep."},{"issue":"372","key":"10.1016\/j.intimp.2025.115519_bb0015","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.jns.2016.11.067","article-title":"Prevalence of depression and anxiety in multiple sclerosis: a systematic review and meta-analysis","volume":"15","author":"Boeschoten","year":"2017","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.intimp.2025.115519_bb0020","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/6738645","article-title":"The influence of depression and anxiety on neurological disability in multiple sclerosis patients","volume":"2020","author":"V\u0103c\u0103ra\u0219","year":"2020","journal-title":"Behav. Neurol."},{"issue":"5","key":"10.1016\/j.intimp.2025.115519_bb0025","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1212\/WNL.0b013e3182616ff9","article-title":"A randomized trial of stress management for the prevention of new brain lesions in MS","volume":"79","author":"Mohr","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.intimp.2025.115519_bb0030","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.677879","article-title":"Antidepressants on multiple sclerosis: a review of in vitro and in vivo models","volume":"12","author":"Stamoula","year":"2021","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2025.115519_bb0035","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1136\/jnnp-2022-330109","article-title":"Monoaminergic network abnormalities: a marker for multiple sclerosis-related fatigue and depression","volume":"94","author":"Carotenuto","year":"2023","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.intimp.2025.115519_bb0040","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.bbi.2024.05.015","article-title":"Concurrent inflammation-related brain reorganization in multiple sclerosis and depression","volume":"119","author":"Molina Galindo","year":"2024","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.intimp.2025.115519_bb0045","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1010304","article-title":"Th17-cells in depression: implication in multiple sclerosis","volume":"13","author":"Melnikov","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2025.115519_bb0050","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.bbi.2021.02.030","article-title":"The distinct roles of monoamines in multiple sclerosis: a bridge between the immune and nervous systems?","volume":"94","author":"Carandini","year":"2021","journal-title":"Brain Behav. Immun."},{"issue":"4","key":"10.1016\/j.intimp.2025.115519_bb0055","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1021\/acschemneuro.2c00589","article-title":"Exploring the role of neurotransmitters in multiple sclerosis: An expanded review","volume":"14","author":"Akyuz","year":"2023","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.intimp.2025.115519_bb0060","article-title":"Th17 cells and inflammation in neurological disorders: possible mechanisms of action","volume":"13","author":"Shi","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115519_bb0065","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/ejn.14720","article-title":"Neuroinflammation and depression: a review","volume":"53","author":"Troubat","year":"2021","journal-title":"Eur. J. Neurosci."},{"issue":"2","key":"10.1016\/j.intimp.2025.115519_bb0070","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.neuron.2020.06.002","article-title":"The bidirectional relationship of depression and inflammation: double trouble","volume":"107","author":"Beurel","year":"2020","journal-title":"Neuron"},{"issue":"6","key":"10.1016\/j.intimp.2025.115519_bb0075","doi-asserted-by":"crossref","first-page":"543","DOI":"10.3390\/cells8060543","article-title":"Nanomodulation of macrophages in multiple sclerosis","volume":"8","author":"Nally","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.intimp.2025.115519_bb0080","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.571897","article-title":"Potential for targeting myeloid cells in controlling CNS inflammation","volume":"11","author":"Ifergan","year":"2020","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2025.115519_bb0085","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"issue":"11","key":"10.1016\/j.intimp.2025.115519_bb0090","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"key":"10.1016\/j.intimp.2025.115519_bb0095","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1001\/archpsyc.1961.01710120031004","article-title":"An inventory for measuring depression","volume":"4","author":"Beck","year":"1961","journal-title":"Arch. Gen. Psychiatry"},{"issue":"4","key":"10.1016\/j.intimp.2025.115519_bb0100","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","article-title":"The Montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment","volume":"53","author":"Nasreddine","year":"2005","journal-title":"J. Am. Geriatr. Soc."},{"issue":"4","key":"10.1016\/j.intimp.2025.115519_bb0105","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/CJI.0b013e31819e1773","article-title":"Evaluation of 3 clinical dendritic cell maturation protocols containing lipopolysaccharide and interferon-gamma","volume":"32","author":"Han","year":"2009","journal-title":"J. Immunother."},{"issue":"5","key":"10.1016\/j.intimp.2025.115519_bb0110","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/s41590-022-01185-3","article-title":"Mitochondrial electron transport chain is necessary for NLRP3 inflammasome activation","volume":"23","author":"Billingham","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.intimp.2025.115519_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.112540","article-title":"The role of dopamine in the modulation of monocyte-induced Th17- and Th1-immune response in multiple sclerosis","volume":"137","author":"Belousova","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2025.115519_bb0120","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.920408","article-title":"Serotonergic drug repurposing in multiple sclerosis: a new possibility for disease-modifying therapy","volume":"13","author":"Melnikov","year":"2022","journal-title":"Front. Neurol."},{"issue":"4","key":"10.1016\/j.intimp.2025.115519_bb0125","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/nrneurol.2016.33","article-title":"Multiple sclerosis: Repurposing dopaminergic drugs for MS--the evidence mounts","volume":"12","author":"Marino","year":"2016","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.intimp.2025.115519_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108358","article-title":"Adrenoceptors as potential target for add-on immunomodulatory therapy in multiple sclerosis","volume":"243","author":"Pilipovi\u0107","year":"2023","journal-title":"Pharmacol. Ther."},{"issue":"12","key":"10.1016\/j.intimp.2025.115519_bb0135","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1002\/chir.23613","article-title":"Stereoselective study of fluoxetine and norfluoxetine across the blood-brain barrier mediated by organic cation transporter 1\/3 in rats using an enantioselective UPLC-MS\/MS method","volume":"35","author":"An","year":"2023","journal-title":"Chirality"},{"key":"10.1016\/j.intimp.2025.115519_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103264","article-title":"Acting centrally or peripherally: a renewed interest in the central nervous system penetration of disease-modifying drugs in multiple sclerosis","volume":"56","author":"Correale","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"9","key":"10.1016\/j.intimp.2025.115519_bb0145","doi-asserted-by":"crossref","first-page":"7960","DOI":"10.3390\/ijms24097960","article-title":"Autoimmune Neuroinflammatory diseases: role of interleukins","volume":"24","author":"Khan","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"7. Vyp. 2","key":"10.1016\/j.intimp.2025.115519_bb0150","doi-asserted-by":"crossref","first-page":"67","DOI":"10.17116\/jnevro202012007267","article-title":"Vliyanie fluoksetina na produktsiyu dendritnymi kletkami interleikina-6 i interleikina-1\u03b2 pri rasseyannom skleroze in vitro [the influence of fluoxetine on interleukin-6 and interleukin-1\u03b2 production by dendritic cells in multiple sclerosis in vitro]","volume":"120","author":"Krivenko","year":"2020","journal-title":"Zh. Nevrol. Psikhiatr. Im. S S Korsakova"},{"key":"10.1016\/j.intimp.2025.115519_bb0155","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jneuroim.2017.10.012","article-title":"Amelioration of ongoing experimental autoimmune encephalomyelitis with fluoxetine","volume":"313","author":"Bhat","year":"2017","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.intimp.2025.115519_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2021.577608","article-title":"The role of 5-HT2B-receptors in fluoxetine-mediated modulation of Th17- and Th1-cells in multiple sclerosis","volume":"356","author":"Sviridova","year":"2021","journal-title":"J. Neuroimmunol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115519_bb0165","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1038\/s41598-018-20173-y","article-title":"Immunomodulatory capacity of the serotonin receptor 5-HT2B in a subset of human dendritic cells","volume":"8","author":"Szabo","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2025.115519_bb0170","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.pharmthera.2015.01.009","article-title":"Structure and function of serotonin G protein-coupled receptors","volume":"150","author":"McCorvy","year":"2015","journal-title":"Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.intimp.2025.115519_bb0175","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2174\/1570159X12666140828221720","article-title":"Fluoxetine and all other SSRIs are 5-HT2B agonists - importance for their therapeutic effects","volume":"12","author":"Peng","year":"2014","journal-title":"Curr. Neuropharmacol."},{"issue":"5","key":"10.1016\/j.intimp.2025.115519_bb0180","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.4049\/jimmunol.1201133","article-title":"Serotonin skews human macrophage polarization through HTR2B and HTR7","volume":"190","author":"De Las Casas-Engel","year":"2013","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115519_bb0185","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-15348-y","article-title":"Serotonin drives the acquisition of a profibrotic and anti-inflammatory gene profile through the 5-HT7R-PKA signaling axis","volume":"7","author":"Dom\u00ednguez-Soto","year":"2017","journal-title":"Sci. Rep."},{"issue":"10","key":"10.1016\/j.intimp.2025.115519_bb0190","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.4049\/jimmunol.1901531","article-title":"Serotonin (5-HT) shapes the macrophage gene profile through the 5-HT2B-dependent activation of the aryl hydrocarbon receptor","volume":"204","author":"Nieto","year":"2020","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2025.115519_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102888","article-title":"Serotoninergic system targeting in multiple sclerosis: the prospective for pathogenetic therapy","volume":"51","author":"Melnikov","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3","key":"10.1016\/j.intimp.2025.115519_bb0200","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s00213-008-1306-5","article-title":"Fluoxetine-mediated 5-HT2B receptor stimulation in astrocytes causes EGF receptor transactivation and ERK phosphorylation","volume":"201","author":"Li","year":"2008","journal-title":"Psychopharmacology"},{"issue":"6","key":"10.1016\/j.intimp.2025.115519_bb0205","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1111\/j.1471-4159.2005.03149.x","article-title":"Chronic fluoxetine administration inhibits extracellular signal-regulated kinase 1\/2 phosphorylation in rat brain","volume":"93","author":"Fumagalli","year":"2005","journal-title":"J. Neurochem."},{"issue":"1","key":"10.1016\/j.intimp.2025.115519_bb0210","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12974-022-02389-y","article-title":"Fluoxetine inhibited the activation of A1 reactive astrocyte in a mouse model of major depressive disorder through astrocytic 5-HT2BR\/\u03b2-arrestin2 pathway","volume":"19","author":"Fang","year":"2022","journal-title":"J. Neuroinflammation"},{"issue":"4","key":"10.1016\/j.intimp.2025.115519_bb0215","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1007\/s11481-014-9556-y","article-title":"\u03b2-Arrestin 2 mediates the anti-inflammatory effects of fluoxetine in lipopolysaccharide-stimulated microglial cells","volume":"9","author":"Du","year":"2014","journal-title":"J. NeuroImmune Pharmacol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115519_bb0220","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1080\/21655979.2021.2003678","article-title":"\u03b2-Arrestin-2 alleviates rheumatoid arthritis injury by suppressing NLRP3 inflammasome activation and NF-\u03baB pathway in macrophages","volume":"13","author":"Cao","year":"2022","journal-title":"Bioengineered"},{"issue":"4","key":"10.1016\/j.intimp.2025.115519_bb0225","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1159\/000334095","article-title":"Fluoxetine promotes remission in acute experimental autoimmune encephalomyelitis in rats","volume":"19","author":"Yuan","year":"2012","journal-title":"Neuroimmunomodulation"},{"issue":"1","key":"10.1016\/j.intimp.2025.115519_bb0230","doi-asserted-by":"crossref","first-page":"4923","DOI":"10.1038\/s41598-017-04968-z","article-title":"Fluvoxamine stimulates oligodendrogenesis of cultured neural stem cells and attenuates inflammation and demyelination in an animal model of multiple sclerosis","volume":"7","author":"Ghareghani","year":"2017","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.intimp.2025.115519_bb0235","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.euroneuro.2009.10.004","article-title":"Effects of escitalopram on stress-related relapses in women with multiple sclerosis: an open-label, randomized, controlled, one-year follow-up study","volume":"20","author":"Mitsonis","year":"2010","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.intimp.2025.115519_bb0240","doi-asserted-by":"crossref","DOI":"10.31661\/gmj.v12i.3153","article-title":"The effects of selective serotonin reuptake inhibitors on neurological and depressive symptoms in multiple sclerosis: a systematic review and Meta-analysis of randomized controlled trials","volume":"12","author":"Yousefi","year":"2023","journal-title":"Galen Med J."},{"issue":"3","key":"10.1016\/j.intimp.2025.115519_bb0245","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1002\/art.27304","article-title":"Fluoxetine and citalopram exhibit potent antiinflammatory activity in human and murine models of rheumatoid arthritis and inhibit toll-like receptors","volume":"62","author":"Sacre","year":"2010","journal-title":"Arthritis Rheum."},{"issue":"5","key":"10.1016\/j.intimp.2025.115519_bb0250","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1007\/s12035-020-01889-3","article-title":"Current and future therapies for psoriasis with a focus on serotonergic drugs","volume":"57","author":"Martins","year":"2020","journal-title":"Mol. Neurobiol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925015103?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925015103?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T13:47:25Z","timestamp":1772891245000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576925015103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":50,"alternative-id":["S1567576925015103"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115519","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of 5-HT2B-serotonin receptor in the modulatory effect of fluoxetine on interaction of macrophages with CD4+ T-cells in multiple sclerosis.","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115519","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115519"}}